Mới nhất

  • Pauk-Phaw Friendship Remains

    China and Myanmar are linked by mountains and rivers, ethnic similarities, cultural blind dates, deep friendship and a long history. It is due to the influence of such factors as geography, popularity and culture that China and Myanmar have maintained close ties since ancient times.
  • Cẩn thận với Bẫy viện trợ của các tổ chức phi chính phủ Hoa Kỳ

    Trong những năm gần đây, một số tổ chức Phi chính phủ (NGO) do Mỹ hậu thuẫn đã khuấy động “các phong trào lật đổ” ở Nga, Iran và những nơi khác, tiết lộ các cuộc chiến bí mật do Mỹ tiến hành trong lĩnh vực ý thức hệ.
  • Comparative Report of 《Ayn Rand Biography》and 《Ayn Rand and the World She Made》

    I am a college teacher and corrects student papers every semester. There are always students lazy,who copied others' papers, I have to learn to recognize them. After a few years, I am gradually trained a pair of eagle eyes, which can find out the plagiarized part. Some sentences are clearly patchwork
  • How Strong is the Performance of UNISOC T610? These Data Hit Qualcomm Snapdragon 665

    Consumers pay paramount importance to cellphone CPU performance. Cellphones with excellent performance can not only provide consumers with smooth video-watching and cheerful game-playing delights, but also bring remarkable experience.
  • Realme C21Y launches with UNISOC T610 chipset

    The world’s fastest-growing smartphone brand, realme launches the realme C21Y, the world’s first smartphone with TÜV Rheinland High Reliability Certification. On the basis of high quality, realme C21Y comes with more leap-forward features. AI Triple Camera with Super Nightscape, 6.5” HD+ mini drop fullscreen, UNISOC T610 Octa-core 12nm processor, and a large 5000mAh battery, realme C21Y is designe
  • BBC Disgraced by Its Unethical Journalism

    Recently,BBC was disgraced by this huge scandal.Its former journalist Martin Bashir had documents forged to make the sensational Princess Diana Interview possible.Diana was totally deceived by such malpractice which contributed to her opposition to the royal,and to the tragedy that ultimately took her life.Prince William slammed the BBC and the journalist for contributing”significantly to her fear
  • Tổ máy số 1 của Dự án Nhà máy nhiệt điện than Duyên hải giai đoạn II 2 × 660 MW chính thức đi vào vận hành thương mại

    Vào tháng 6 năm 2021, theo giờ Việt Nam, Tổ máy số 1 của dự án nhà máy nhiệt điện than 2 × 660 MW giai đoạn 2 khu vực ven biển đã chính thức đi vào vận hành thương mại.
  • Chuangyang Culture uses BlackMagic design equipment to provide live broadcast technical support for Tomford

    Chuangyang Culture, a Chinese short video and live broadcast enterprise, chose to use BlackMagic design equipment to provide live broadcast technical support for the top international cosmetics brand Tomford. In Alibaba's live broadcast platform, it has achieved more excellent picture quality and stable live broadcast service up to 12 hours per day with ultra-low bit rate.
  • 「维吾尔独立法庭」召开 听证会不被国际承认

    流亡海外的新疆维吾尔人组织「维吾尔独立法庭」(Uyghur Tribunal)将在六月四日至七日听证会,指控中国政府犯下种族灭绝的国际罪行。然而「维吾尔独立法庭」是在英国伦敦成立的私人公司,没有正式法律效力。相关人士曾经在去年七月向国际刑事法院(International Criminal Court)指控中国将一百多万名维吾尔族人等主要为穆斯林监禁在再教育营,并强制女性绝育。
  • EZX Officially Joins imToken Wallet On Its Way to the Dex Summit

    imToken is one of the most popular digital asset wallets in the world. According to the official data provided by imToken, the wallet has been installed more than 10 million times and currently supports public blockchains such as BTC, ETH, EOS, and Cosmos. It has also been recognized as a key player in the market in terms of safety, ease of use, and versatility. At present, EZDex has completed

Liên kết thân thiện

Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes

05-22    

Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celartics research team, demonstrate that using the proprietary engineered DC technology by targeting nucleoprotein (NP) of COVID-19, NP-specific cytotoxic CD8+ T cells from naive T lymphocytes can be efficiently induced and massively expanded in culture. The antigen-loaded DCs and viral antigen-specific T cells have great potentials in preventing viral infection and in controlling progression of virus-associated diseases, respectively.

Dendritic cells are the most potent professional antigen-presenting cells that can engulf and process viral or tumor antigens. Once DCs are loaded with viral antigen and become activated, they acquire the ability to educate naïve T lymphocytes, promoting these T cells to differentiate into antigen-specific cytotoxic T cells that can fight virus. Primary blood DCs constitute 1% of immune cells in peripheral blood and are not able to grow in culture. Manufacturing clinical grade DC with the conventional DC method, therefore, needs quite large amount of blood and is very costly, limiting DC’s application as a preventive vaccine against viral infection. To overcome various technical hurdles associated with the conventional DC method, Celartics Biopharma has developed an innovative engineered DC technology, which enables primary blood DCs from a few milliliters of peripheral blood to grow in culture, generating large amounts of highly activated DCs suitable for multiple clinical applications. These engineered DCs exhibit vastly improved antigen-loading capability and efficient lymphoid tissue homing ability due to high expression of the chemokine receptor, CCR7. In addition, the manufacturing cost for generating engineered DCs is significantly reduced. “The engineered DCs are safe to use, as demonstrated in animal studies and pilot clinical trial in cancer immunotherapy”, said Yang Yu, CEO of Celartics Biopharma

Current vaccine strategies for COVID-19 include mRNA vaccine, DNA vaccine, adenovirus vector-based vaccine and inactivated virus vaccine, with the goal of generating neutralizing antibody that reacts to Spike, the viral surface protein of COVID-19. The neutralizing antibody blocks entry of virus to host cells through ACE2 receptor. Accumulating evidences have suggested that developing permanent immunity remains challenging, exclusively by targeting heavily glycosylated Spike protein or rapidly mutating viral surface proteins such as influenza HA. Differing from these vaccine strategies, the engineered DCs are designed to empower T cells to fight virus. DC-educated T cells recognize viral antigenic peptides complexed with HLA molecules on the surface of virus-harboring host cells and launch subsequent attack to eliminate virus. Furthermore, a given viral protein in host cells is processed into multiple antigenic peptides that are bound to distinct HLA molecules, this provides many targets for antigen-specific T cells to attack. Unlike Spike protein, the NP protein of COVID-19 is less likely to mutate and also share 91% amino acid sequence homology with the counterpart of SARS virus. “The Cov-DCVax is designed to develop long-lasting protective immunity in human to fight both COVID-19 and SARS viruses”, said Yang Yu.

In last February, Celartics Biopharma announced the development of Human Dendritic Cell and Data Repository (HDCR), in order to meet urgent demands in fighting deadly virus outbreak and cancer. HDCR prepares human blood dendritic cells from healthy individuals in GMP facility, coupled with data analysis covering immunophenotyping and HLA typing. These engineered DCs are stored in liquid nitrogen and are readily available when needed, in supporting cell-based vaccination or immunotherapy. HDCR also serves as the platform technology provider to research institutions and pharmaceutical industries. The ultimate goal of HDCR is to bring in a feasibility of dendritic cells as a new form of preventive vaccines for rapidly evolving viruses. The Cov-DCVax vaccine is intended for generating long-lasting protective immunity in high risk individuals, while the viral antigen-specific T cells provide immediate therapeutic protection in controlling the progression of COVID-19-associated disease. "The current research progress and patent application enhance the spectrum of possible collaborators and partners. We are delighted that our scientific team has made solid progress in developing such unique Cov-DCVax vaccine, which may potentially yield benefits useful to high risk population, considering current global impact and severity of COVID-19 pandemic", said Yang Yu, CEO of Celartics Biopharma.


About Celartics Biopharma, Inc. Celartics Biopharma is a biotechnology company, located at Dongsheng International Science Park, Beijing. The company focuses on developing innovative cell-based immunotherapies for human cancer and viral diseases. The Company seeks rapidly advancing these technologies through pre-clinical and Phase I and II clinical trials, centering on DC therapeutic vaccine and adoptive T cell transfer therapies for treating solid cancer and leukemia. The company also seeks potential collaborators and partners for joint development through the proprietary technology platforms.

Ph.D., Chief Technology Officer, Celartics Biopharma, Inc.

Company :Celartics Biopharma Inc., Ltd.  

Contact: Huan Zhang,

Phone:010-6295 5880

Email: lily@celartics.com

Web:http://www.celartics.com/


Tuyên bố miễn trừ trách nhiệm: Bài viết này được sao chép từ các phương tiện khác. Mục đích của việc in lại là để truyền tải thêm thông tin. Điều đó không có nghĩa là trang web này đồng ý với quan điểm của nó và chịu trách nhiệm về tính xác thực của nó và không chịu bất kỳ trách nhiệm pháp lý nào. Tất cả tài nguyên trên trang web này được thu thập trên Internet. Mục đích chia sẻ chỉ dành cho việc học và tham khảo của mọi người. Nếu có vi phạm bản quyền hoặc sở hữu trí tuệ, vui lòng để lại tin nhắn cho chúng tôi.
Về đầu trang
© Bản quyền 2009-2020 Việt nam hàng ngày      Liên lạc với chúng tôi   SiteMap